{"id":148673,"date":"2023-06-15T08:19:10","date_gmt":"2023-06-15T12:19:10","guid":{"rendered":"https:\/\/44.250.171.167\/?p=148673"},"modified":"2023-06-15T08:19:12","modified_gmt":"2023-06-15T12:19:12","slug":"sastasundar-ventures-a-new-player-in-the-e-pharmacy-space","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sastasundar-ventures-a-new-player-in-the-e-pharmacy-space\/","title":{"rendered":"SastaSundar Ventures – A new player in the e-pharmacy space"},"content":{"rendered":"\n

\u201cWe spent last few years building most efficient Digital Healthcare Platform in terms of Cost, Consumer Experience and Capital. The continued focus on bringing efficiency everywhere has played significant role in developing very differentiated model. The firm belief of not chasing \u201cGrowth at any cost model\u201d rather building unique \u201cSustainable Growth model\u201d has been proven to be the right strategy.<\/em>“<\/p>

<\/p>Mr. Ravi Kant Sharma, Chief Executive Officer<\/cite><\/blockquote>\n\n\n\n

<\/div>\n\n\n\n

Stock data<\/strong><\/h3>\n\n\n\n
Ticker<\/strong><\/td>SASTASUNDR<\/td><\/tr>
Exchange<\/strong><\/td>BSE and NSE<\/td><\/tr>
Industry<\/strong><\/td>Finance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
Price Performance:<\/strong><\/h5>\n\n\n\n
Last 5 days<\/strong><\/td>+1.75%<\/td><\/tr>
YTD<\/strong><\/td>+3.87%<\/td><\/tr>
Last 1 year<\/strong><\/td>+3.76%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n

Company description:<\/strong><\/h3>\n\n\n\n

Sastasundar Ventures Limited is a Core Investment Company (CIC) focusing on the business of digital networks of healthcare and portfolio management services. The Company aims to provide healthcare services at a reasonable cost with its innovative information and knowledge based web portal.<\/p>\n\n\n\n

SastaSundar Digital Healthcare Network:<\/strong><\/p>\n\n\n\n

The Sastasundar Digital Healthcare business consists of Digital Platforms for Healthcare and Financial Services. The Digital Platforms of Healthcare form a substantial part of its business. It\u2019s a partnership between online to offline, digital to personal, AI to hug, and cloud to local care, which facilitates consistent access to affordable healthcare in a convenient manner.\u00a0<\/p>\n\n\n\n

Market Expansion<\/strong><\/p>\n\n\n\n

In FY20, the co. had set up its 3rd Area Logistic Centre (ALC) in Mumbai. The company has 3 operational ALCs, with 400+ chemists, and has also expanded its Healthbuddy Network in 8 States.<\/p>\n\n\n\n

Rapid Growth:<\/strong><\/p>\n\n\n\n

During FY22, for RetailerShakti, (B2B digital healthcare platform), GMV has grown by close to 55% and GENU Path Labs, (diagnostic vertical), revenue has grown by 89%. <\/p>\n\n\n\n

Share acquisition by Flipkart Health+<\/strong><\/p>\n\n\n\n

During FY22, Flipkart acquired a majority share in Sastasundar Marketplace Limited which owns and operates SastaSundar.com as its foray into the healthcare space. <\/p>\n\n\n\n

Share Purchase Agreement (SPA):<\/strong><\/p>\n\n\n\n

The company entered into a Share Purchase Agreement (SPA) with Genu Path Labs Limited and Sastasundar Healthbuddy Limited in March 2019. It sold the investment in Genu Path Labs Limited to Sastasundar Healthbuddy Limited for a consideration of Rs. 6 crores.<\/p>\n\n\n\n

Subsidiaries:<\/strong><\/p>\n\n\n\n

SastaSundar Ventures has 10 subsidiaries out of which Sastasundar Healthbuddy Limited and Retailer Shakti Supply Chain Private Limited contribute 45% of total consolidated revenue.<\/p>\n\n\n\n

Foreign Investors:<\/strong><\/p>\n\n\n\n

The company is Backed by Globally Acclaimed Investors including Mitsubishi Corporation Japan and Rohto Pharmaceutical company Ltd. <\/p>\n\n\n\n

Investments:<\/strong><\/p>\n\n\n\n

On a consolidated basis the company holds investments worth Rs. 670 crores as of March 2022 compared to Rs. 43 crores in March 2021. Investments are made in mutual funds and equity shares of various companies. <\/p>\n\n\n\n

Financials:<\/strong><\/h5>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
<\/div>\n\n\n\n

What we like:<\/strong>    <\/h3>\n\n\n\n
  1. Robust management having eyes on the goal:<\/strong><\/li><\/ol>\n\n\n\n

    The problem with investing in a startup\/ PE type of company is the high cash burn it entails and the possibility of never reaching profitability. Compared to other peers, SastaSundar has done incredibly well to avoid a lot of cash burn. The company has substantially reduced loss from 30 crores for 9 months FY 20 to around 5 crores for 9 months FY 21. The company is trading almost at breakeven with -1\/-2 percent margins which is commendable in an industry where the margins for other bigger companies are at anywhere from -25% to -89%.<\/p>\n\n\n\n

    The management in its annual report in 2019 had given a guidance of growth of 5 million orders in FY 19-20. The same was fulfilled in 11 months. The management in its annual report in 2020 has given a guidance of growth of over 10 million orders in FY 2020-21, whether the same has been fulfilled will be analyzed whenever the records are released.<\/p>\n\n\n\n

    1. Growth in e-diagnostics space:<\/strong><\/li><\/ol>\n\n\n\n

      SastaSundar Healthbuddy Limited has forayed into e-diagnostics space via Genu Paths Labs and the same is growing as planned. Health data from medicine sales integrated with the lab\u2019s data has tremendous potential and personalized health-tech is the future of healthcare. The company had 1.2 lakhs tests in 2020.<\/p>\n\n\n\n

      1. Strong growth backed by Japanese MNC\u2019s:<\/strong><\/li><\/ol>\n\n\n\n

        The company has compounded sales growth by 65 percent CAGR over the past 5 years and almost 96 percent over the past 3 years. The company is in further talks to raise money to go national which shows despite the tough competition in the E-pharmacy space, the company also has investors with deep pockets and the offline to online model can be a significant disruptor in the healthcare space.<\/p>\n\n\n\n

        <\/div>\n\n\n\n

        Factors to consider:<\/strong><\/h3>\n\n\n\n
        1. Strong competition<\/strong>:<\/li><\/ol>\n\n\n\n

          The e-pharmacy space has brutal competition with players with very deep pockets as mentioned earlier which can result in a 2-3 player consolidation style model like Cab Aggregators (Ola and Uber), Food delivery(Zomato and Swiggy) and online B2C marketplace(Amazon, Flipkart).<\/p>\n\n\n\n

          1. Low Float\/ Illiquid stock:<\/strong><\/li><\/ol>\n\n\n\n

            The company has only around 200 crores worth of free float, which makes entry\/exit of any large player extremely difficult and not without some sharp increase and decrease.<\/p>\n\n\n\n

            1. Business Model change:<\/strong><\/li><\/ol>\n\n\n\n

              The company was earlier a Financial service entity and had tried to venture into digital marketing, brand promotion, food processing and then pivoted into e-pharmacy which is not a very common route. Though it doesn\u2019t impact what the company is doing currently, it is still a minor sign of concern.<\/p>\n\n\n\n

              1. Holding company discount:<\/strong><\/li><\/ol>\n\n\n\n

                If we take a prospective valuation of 2x sales, the underlying company should be valued at around 1100 crores. In India, where the holding company discount is much sharper even for larger companies like Bajaj Holdings, that could be a case of concern if the company fails to deliver in the growth area<\/p>\n","protected":false},"excerpt":{"rendered":"

                \u201cWe spent last few years building most efficient Digital Healthcare Platform in terms of Cost, Consumer Experience and Capital. The continued focus on bringing efficiency everywhere has played significant role in developing very differentiated model. The firm belief of not chasing \u201cGrowth at any cost model\u201d rather building unique \u201cSustainable Growth model\u201d has been proven […]<\/p>\n","protected":false},"author":1863,"featured_media":148504,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,5747,6352],"tags":[8975,12209,8749],"class_list":["post-148673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-healthcare-stocks","category-research-summary","tag-diagnostics-research","tag-healthtech","tag-retail-pharmacy"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/iStock-97234232.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":133381,"url":"https:\/\/alphastreet.com\/india\/apollo-hospitals-research-report-at-a-glimpse\/","url_meta":{"origin":148673,"position":0},"title":"Apollo Hospitals research report at a glimpse","author":"Chirag Gupta","date":"August 17, 2022","format":false,"excerpt":"Stock Data: TickerAPOLLOHOSPExchangeBSE and NSE\u00a0IndustryHealthcare Why is the stock price rising? Shares of Apollo Hospitals Enterprise Ltd have gained 8.84% over the past month, an indication that the June quarter performance has buoyed investor sentiment. The hospital business grew 26% sequentially and 145% year-on-year (y-o-y), with an improved occupancy level.\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179214,"url":"https:\/\/alphastreet.com\/india\/medplus-health-reports-26-profit-surge-in-q3-on-robust-pharmacy-expansion\/","url_meta":{"origin":148673,"position":1},"title":"MedPlus Health Reports 26% Profit Surge in Q3 on Robust Pharmacy Expansion","author":"Staff Correspondent","date":"February 2, 2026","format":false,"excerpt":"MedPlus Health Services Limited (NSE: MEDPLUS) reported a strong financial performance for the third quarter ended December 31, 2025, with net profit climbing 26% year-on-year. The results, underpinned by a 15.7% increase in revenue, highlight the company\u2019s success in scaling its pharmacy network beyond Tier-1 cities and improving store-level unit\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":147986,"url":"https:\/\/alphastreet.com\/india\/apollo-hospitals-enterprise-limited-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":148673,"position":2},"title":"Apollo Hospitals Enterprise Limited Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"June 1, 2023","format":false,"excerpt":"Key highlights from Apollo Hospitals Enterprise Limited (APOLLOHOSP) Q4 FY23 Earnings Concall Management Update: [00:08:21] APOLLOHOSP said it has made significant progress in inorganic expansion plans, aiming to add 2,000 beds and improve hospital occupancy to 70% by the end of FY '24. Q&A Highlights: [00:12:13] Damayanti Kerai from HSBC\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127676,"url":"https:\/\/alphastreet.com\/india\/apollo-hospitals-enterprise-ltd-apollohosp-q3-fy22-earnings-concall-transcript\/","url_meta":{"origin":148673,"position":3},"title":"Apollo Hospitals Enterprise Ltd (APOLLOHOSP) Q3 FY22 Earnings Concall Transcript","author":"Staff Correspondent","date":"February 12, 2022","format":false,"excerpt":"Apollo Hospitals Enterprise Limited\u00a0(NSE: APOLLOHOSP) Q3 FY22 Earnings Concall dated Feb. 12, 2022 Corporate Participants: Mayank Vaswani\u00a0--\u00a0Investor Relations Suneeta Reddy\u00a0--\u00a0Managing Director Dr. D. Obul Reddy\u00a0--\u00a0Chief Executive Officer of Apollo Pharmacy Chandra Sekhar Chivukula\u00a0--\u00a0President of Corporate and International Sanjiv Gupta\u00a0--\u00a0Chief Financial Officer at Apollo 24|7 Analysts: Prakash Agarwal\u00a0--\u00a0Axis Capital -- Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133889,"url":"https:\/\/alphastreet.com\/india\/the-story-behind-ugro-capital-limited\/","url_meta":{"origin":148673,"position":4},"title":"The Story Behind Ugro Capital Limited","author":"Karan_Singh","date":"September 14, 2022","format":false,"excerpt":"Stock DataTickerUGROCAPExchangeNSE and BSEIndustryNBFC Price PerformanceLast 1 Month+12.31%YTD+1.98%Last 12 Months+71.63% \u201cOur belief is that like consumer credit business in India, the small business financing is also rapidly embracing data driven underwriting. Since the start of demonetisation and advent of GST and creation of three layers of India data stack is\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/09\/iStock-1419155166.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/09\/iStock-1419155166.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/09\/iStock-1419155166.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/09\/iStock-1419155166.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":148586,"url":"https:\/\/alphastreet.com\/india\/apollo-hospital-the-one-stop-healthcare-service\/","url_meta":{"origin":148673,"position":5},"title":"Apollo Hospital: The one stop healthcare service","author":"Chirag Gupta","date":"June 9, 2023","format":false,"excerpt":"\u201cAt a time when the world is realizing the importance of prevention more than ever before, it is a matter of pride that Apollo has been at the forefront of this shift, recognizing that the best way to fight disease is to prevent it in the first place. One of\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/iStock-1303865449.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/148673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=148673"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/148673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/148504"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=148673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=148673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=148673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}